STOCK TITAN
  1. Home
  2. News
  3. SGMO

Sangamo Therapeutics Inc - SGMO STOCK NEWS

Welcome to our dedicated news page for Sangamo Therapeutics (Ticker: SGMO), a resource for investors and traders seeking the latest updates and insights on Sangamo Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sangamo Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sangamo Therapeutics's position in the market.

News
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Rhea-AI Summary
Sangamo Therapeutics (SGMO) will present neurology-focused pre-clinical data at the 27th ASGCT Annual Meeting, showcasing advancements in zinc finger epigenetic regulation, AAV capsid engineering, and Modular Integrases. The data will highlight potential genomic medicine treatments for neurological conditions like prion disease, tauopathies, ALS, Parkinson's, and more.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences clinical trial
-
News
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
Rhea-AI Summary
Sangamo Therapeutics, Inc. (SGMO) announces a securities purchase agreement with institutional investors for the sale of common stock and warrants, expecting to raise approximately $24.0 million. The offering includes 24,761,905 shares of common stock and pre-funded warrants for 3,809,523 shares, priced at $0.84 per share and $0.83 per pre-funded warrant. The warrants will become exercisable after six months, with an exercise price of $1.00 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.55%
Tags
offering
-
News
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Sangamo Therapeutics, Inc. (SGMO) reported significant advancements in their neurology pipeline with promising data on their novel proprietary AAV capsid, STAC-BBB, demonstrating potent gene repression in non-human primates. The company announced progress in chronic neuropathic pain and prion disease programs, with IND and CTA submissions expected in 2024 and 2025. FDA alignment for potential approval and EMA PRIME eligibility for Fabry disease treatment were also highlighted. Financially, Sangamo reported a consolidated net loss for Q4 2023, with revenues decreasing primarily due to collaboration agreement impacts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.26%
Tags
earnings
News
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
Rhea-AI Summary
Sangamo Therapeutics, Inc. announced preclinical data on its novel AAV capsid variant, STAC-BBB, showing robust penetration of the blood-brain barrier and high transgene expression in non-human primates. The capsid enabled delivery of zinc finger payloads targeting prion disease and tauopathies, resulting in potent repression of target genes. STAC-BBB could potentially unlock multiple neurology epigenetic regulation programs, with plans to file up to three neurology IND submissions by end of 2025. The company aims to develop best-in-class neurology medicines using innovative capsid delivery technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.26%
Tags
none
-
News
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
Rhea-AI Summary
Sangamo Therapeutics, Inc. (SGMO) will release its Q4 and full-year 2023 financial results on March 13, 2024. A conference call will follow to discuss financial performance and business updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.26%
Tags
none
-
News
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
Rhea-AI Summary
Sangamo Therapeutics (SGMO) receives positive regulatory updates for isaralgagene civaparvovec gene therapy for Fabry disease from FDA and EMA, potentially expediting approval process and reducing costs. Company actively seeking collaboration partner for further development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
42.11%
Tags
none
News
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
Rhea-AI Summary
Sangamo Therapeutics, Inc. announces updated preliminary data from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, a gene therapy product candidate for the treatment of Fabry disease. The data shows durable safety and preliminary efficacy, including sustained elevated alpha-galactosidase A (α-Gal A) activity, reduced immunogenicity, stable renal function, and significant improvements in overall disease severity, quality of life, and gastrointestinal symptoms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
clinical trial
-
News
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Sangamo Therapeutics, a genomic medicines company, announced progress on its strategic transformation and a restructuring of operations. The company is focusing on neurology-focused genomic medicine and epigenetic regulation therapies for neurological diseases. They have dosed 25 patients in a Phase 1/2 study for Fabry disease, with promising clinical data. They are deferring investments in Phase 3 planning and actively seeking collaboration partners or investors for CAR-Treg cell therapy programs. The company is also shutting down its Brisbane headquarters and reducing its US workforce by 40%, with cost savings expected to reduce operating expenses by 50%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.03%
Tags
earnings
-
News
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
Rhea-AI Summary
Sangamo Therapeutics to Release Third Quarter 2023 Financial Results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
earnings
News
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
Rhea-AI Summary
Sangamo Therapeutics announces acceptance of six abstracts for presentation at the 30th Annual Congress of the European Society of Gene & Cell Therapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences clinical trial
Stock SGMO logo
Sangamo Therapeutics Inc

Nasdaq:SGMO

SGMO Rankings

#4232 Ranked by Market Cap
#5455 Ranked by Stock Gains
N/A Ranked by Dividends

SGMO Stock Data

110.67M
165.08M
9.45%
49.93%
5.6%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Brisbane

About SGMO

for sangamo therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. to learn more about sangamo, visit the our website at www.sangamo.com.